Response to Clenbuterol in Humans

University of Copenhagen

Status: Completed

Conditions: Healthy

Treatments: Drug: Placebo; Drug: Clenbuterol Oral Product

Study type: Interventional

Funder types: Other

Identifiers

NCT03860870

CLEN

Details and patient eligibility

About

Due to the long half-life (~36 hr) of clenbuterol, detection methods such as dried blood spots (DBS) are a potentially suitable method to easily and non-invasively detect doping misuse of this compound for several days after ingestion. If, and how long, the compound can be detected by DBS has not yet been investigated but is of interest due to its potential in doping-control. The aim is to evaluate whether abuse of clenbuterol can be detected at relevant concentration levels in samples obtained using DBS and to assess the physiological response to clenbuterol in skeletal muscle..

Enrollment: 16 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy
• Male
• 18-40 years of age
• No known contraindications for anabolic drugs (e.g. cancer)

Exclusion criteria

• Abnormal ECG
• Steroid abuse
• Ongoing use of prescription medication
• heavy resistance training more than 2 times weekly
• Disease deemed by the MD to infer a risk to participate in the trial

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

16 participants in 2 patient groups, including a placebo group

Clenbuterol

Experimental group

Description:

Subjects ingest 80 micrograms of clenbuterol tablets

Treatment:

Drug: Clenbuterol Oral Product

Placebo

Placebo Comparator group

Description:

Subjects ingest placebo tablets

Treatment:

Drug: Placebo